Humanetics Completes Phase I Safety and Pharmacokinetic Trial for New Radiation Countermeasure
MINNEAPOLIS--(BUSINESS WIRE)--Humanetics Corporation today announced the successful completion of the Company’s Phase I human trial for BIO 300, a medical radiation countermeasure. Humanetics is seeking approval to market BIO 300 as a new drug for the prevention and mitigation of Acute Radiation Syndrome (ARS), a potentially lethal condition for which there are currently no FDA-approved treatments.